Clonorchiasis

Summary

Clonorchiasis (MONDO:0005705) is a disease and 1 clinical trial. Top therapeutic interventions include albendazole and praziquantel. A subtype of helminthiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	clonorchiasis
Mondo ID	MONDO:0005705
EFO	EFO:0007210
MeSH	D003003
Orphanet	658917
DOID	DOID:13767
ICD-10-CM	B66.1
ICD-11	918986134
SNOMED CT	11938002
UMLS	C0009021
MedGen	3119
GARD	0024222
Is cancer (heuristic)	no

Also known as: Oriental liver fluke disease

Disease family

This is a subtype of helminthiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › clonorchiasis

Related subtypes (21): acanthocephaliasis, heterophyiasis, metagonimiasis, fascioliasis, fasciolopsiasis, monieziasis, dicrocoeliasis, echinostomiasis, fascioloidiasis, gnathomiasis, hymenolepiasis, necatoriasis, Nematoda infectious disease, opisthorchiasis, paragonimiasis, trichostrongyloidiasis, schistosomiasis, filariasis, angiostrongyliasis, intestinal helminthiasis, Cestode infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07074444	PHASE4	RECRUITING	Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALBENDAZOLE	4	1
PRAZIQUANTEL	4	1
CHEMBL3264245	0	1
TRIBENDIMIDINE	0	1